Magic mushrooms treat depression, anxiety felt by cancer patients; Merck wins a speedy review schedule for latest Keytruda initiative
Yesterday’s story about the potential use of an illicit drug for a neuropsychiatric condition focused on MDMA (ecstasy) for post-traumatic stress disorder. Today we got word of two small studies that explored the powerful impact of psilocybin (magic mushrooms) in combatting depression and anxiety among cancer patients. Not only did the psychedelic drug do the trick for most of the patients, improving a sense of well-being and satisfaction, many also felt it was one of the most valuable experiences of their lives. And the treatment effect lasted a bullishly long six months from a single dose.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.